Reduced sustained component of exocytosis and calcium charge transfer (QCa) can be partially rescued by Cabp2-transgene-expression.
(A) Capacitance increments with the corresponding QCa were probed by different depolarization durations from a holding potential of - 85 mV (unpaired t tests with Welch correction). CaBP1/2-deficient IHCs showed significant impairment of the sustained exocytosis (p < 0.05 for 20-ms, and < 0.001 for 100- and 200-ms step, respectively) and reduced cumulative Ca2+ influx (p < 0.005 for the longest two pulses) as compared to WT controls (black asterisks). AAV-mediated delivery of Cabp2 improved IHC synaptic function as compared to non-injected Cabp1/2-DKO controls (p < 0.01 for ΔCm upon 100- and 200-ms step, and p < 0.05 for QCa upon 200-ms step; green asterisks). (B) Representative Ca2+-current traces and corresponding membrane capacitance changes upon 100-ms long depolarization steps to the peak Ca2+-current potential. (C) Note a reduced efficiency of Ca2+-dependent exocytosis (p < 0.005 for the two longest test pulses; black asterisks), which can be efficiently rescued by intracochlear delivery of PHP.eB-Cabp2 (p < 0.01 and 0.05 for 100- and 200-ms pulse, respectively; green asterisks). (D) Capacitance measurements at a holding potential of -55 mV reveal an aggravation of the phenotype by additional activation of calcium channels between the test pulses (p < 0.01 for 50-ms, and p < 0.005 for 20-, 100- and 200-ms pulse) and a further discrepancy between the QCa of WT and CaBP1/2-deficient IHCs (2-10 ms: p < 0.05; 20-200 ms: p < 0.001). Also in these recording conditions, the IHCs from Cabp2-injected Cabp1/2-DKO animals showed increased QCa (20-200 ms: p < 0.05) and exocytosis (100-200 ms: p < 0.005) as compared to non-injected controls. (E) Capacitance increments and the corresponding QCa upon 100-ms depolarization steps as recorded in different conditions. Note worsening of the phenotype with increasing IHC activation between the test pulses.